世界各国のリアルタイムなデータ・インテリジェンスで皆様をお手伝い

ダイレクト・トゥ・コンシューマー・ラボラトリー検査市場(検査タイプ。遺伝子検査、疾病リスク評価検査、CBC、慢性疾患検査、COVID-19検査、TSH検査、その他;サンプルタイプ。検査タイプ:血液、唾液、尿、その他;プロバイダー:。欧州の産業分析、サイズ、シェア、成長、傾向、予測、2021-2031年


Direct-to-Consumer Laboratory Testing Market (Test Type: Genetic Testing, Disease Risk Assessment Testing, CBC, Chronic Disease Testing, COVID-19 Testing, TSH Testing, and Others; Sample Type: Blood, Saliva, Urine, and Others; and Provider: Hospitals, Clinics, Specialty Labs, and Diagnostic Centers) - Europe Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2021-2031

欧州のダイレクト・ツー・コンシューマー・ラボラトリー検査市場 - レポートの範囲 TMRの調査レポート「欧州の消費者向け直接検査市場」は、2021年から2031年までの予測期間における市場の指標に関する貴重な... もっと見る

 

 

出版社 出版年月 電子版価格 ページ数 言語
Transparency Market Research
トランスペアレンシーマーケットリサーチ
2021年11月15日 US$5,795
シングルユーザーライセンス
ライセンス・価格情報・注文方法はこちら
197 英語

 

サマリー

欧州のダイレクト・ツー・コンシューマー・ラボラトリー検査市場 - レポートの範囲

TMRの調査レポート「欧州の消費者向け直接検査市場」は、2021年から2031年までの予測期間における市場の指標に関する貴重な洞察を得るために、過去だけでなく現在の成長動向と機会についても調査しています。本レポートでは、2020年を基準年、2031年を予測年として、2017年から2031年までの欧州の消費者直販型ラボラトリーテスト市場の売上高を提供しています。また、予測期間における欧州の消費者向け直接検査市場の複合年間成長率(CAGR)を記載しています。

本レポートは、広範な調査を経て作成されました。一次調査では、アナリストが業界のリーダーやオピニオンメーカーにインタビューを行うなど、大規模な調査活動を行いました。二次調査では、主要企業の製品資料、年次報告書、プレスリリース、関連文書などを参照し、欧州の消費者直販型ラボ検査市場を理解するために実施しました。

二次調査には、インターネット上の情報源、政府機関の統計データ、ウェブサイト、業界団体も含まれます。アナリストは、欧州の消費者直販型ラボ検査市場における様々な現象を研究するために、トップダウンとボトムアップのアプローチを組み合わせて採用しました。

本レポートには、精緻なエグゼクティブサマリー、調査範囲に含まれる様々なセグメントの成長挙動に関するスナップショットが含まれています。さらに、欧州の消費者直販型ラボ検査市場における競争力学の変化についても光を当てています。これらの指標は、既存の市場関係者だけでなく、欧州の消費者向けラボラトリーテスト市場への参入に関心を持つ事業者にとっても貴重なツールになります。消費者直接検査市場レポートの次のセクションでは、主要産業イベント(ライセンス提携/M&A)、地域/国別の疾患疫学、COVID-19パンデミックの産業への影響(バリューチェーンと短期/中期/長期の影響)、ヨーロッパの消費者直接検査市場で事業を行うトッププレイヤーの主要成功要因などのUSPをハイライトしています。

また、欧州の消費者向け直接検査市場の競争環境についても掘り下げています。欧州の消費者直販型ラボラトリーテスト市場で活動する主要企業が特定され、これらの各企業は特徴的なビジネス属性についてプロファイルされています。会社概要、財務状況、最近の開発、戦略的概要、SWOTは、本レポートで紹介された欧州の消費者向け直接検査市場におけるプレーヤーの属性の一部です。

欧州の消費者向けラボラトリーテストの市場レポートで回答された主要な質問

市場の主な推進要因、阻害要因、機会は何か?
欧州の消費者直販型ラボ検査市場における予測期間中の主要セグメントの収益シェア予測は?
2031年までに欧州の消費者直販型ラボラトリーテスト市場を収益面でリードするのはどのセグメントか?
技術開発によって欧州の消費者直販型ラボラトリーテスト市場の範囲はどのように広がっているのか?
欧州の消費者直販型ラボラトリーテスト市場で事業を展開する各企業の市場地位はどうなっているのか?
欧州の消費者直販型ラボラトリーテスト市場 - 調査目的と調査方法

欧州の消費者向け直接検査市場に関する包括的なレポートは、まず市場の概要を説明し、次に本調査の範囲と目的について述べます。これに続いて、本調査の目的および欧州の消費者直販型ラボラトリー検査市場の調査範囲において認定機関が定めた医療コンプライアンスについて詳細に説明しています。続いて、市場導入、市場力学、欧州の消費者直接検査市場の概要が記載されており、欧州の消費者直接検査市場の成長に影響を与える市場促進要因、阻害要因、機会に関するTMR分析が記載されています。さらに、欧州の消費者直販ラボラトリーテスト市場のYo-Yトレンドを理解するために、精巧な洞察によるYo-Y分析が提供されています。

本レポートは、読みやすさを考慮し、各セクションを細分化した章立てで編集されています。レポート全体は、グラフと表が適切に配置された網羅的なコレクションで構成されています。主要セグメントの実績値と予測値を絵で表現することで、読者に視覚的にアピールしています。これにより、過去と予測期間終了時の主要セグメントの市場シェアを比較することができます。

本レポートでは、欧州の消費者向け直接検査市場を、検査タイプ、サンプルタイプ、プロバイダ、国の観点から分析しています。各基準における主要セグメントを詳細に調査し、2031年末時点の各セグメントにおける市場シェアも掲載しています。このような貴重な洞察は、市場関係者が消費者直接ラボラトリー検査市場への投資について、情報に基づいたビジネス上の意思決定を行うことを可能にします。


ページTOPに戻る


目次

1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Europe Direct-to-Consumer Laboratory Testing Market
4. Market Overview
4.1. Introduction
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Europe Direct-to-Consumer Laboratory Testing Market Analysis and Forecast, 2017–2031
4.4.1. Market Revenue Projections (US$ Mn)
5. Key Insights
5.1. Key Industrial Events (licensing partnerships/mergers & acquisitions)
5.2. Disease Prevalence & Incidence Rate
5.3. COVID-19 Pandemic Impact on Industry (value chain and short / mid / long term impact)
6. Europe Direct-to-Consumer Laboratory Testing Market Analysis and Forecast, by Sample Type
6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Market Value Forecast, by Sample Type, 2017–2031
6.3.1. Blood
6.3.2. Urine
6.3.3. Saliva
6.3.4. Others
6.4. Market Attractiveness Analysis, by Sample Type
7. Europe Direct-to-Consumer Laboratory Testing Market Analysis and Forecast, by Test Type
7.1. Introduction & Definition
7.2. Key Findings / Developments
7.3. Market Value Forecast, by Test Type, 2017–2031
7.3.1. Genetic Testing
7.3.1.1. Nutrigenetics Test
7.3.1.1.1. Weight Control
7.3.1.1.2. Lactose Intolerance
7.3.1.1.3. Others
7.3.1.2. Celiac Disease Test
7.3.1.3. Sports & Physical Activity Testing
7.3.1.4. Men's Health Tests
7.3.1.5. Women's Health Tests
7.3.1.6. Pregnancy & Prenatal Screening Test
7.3.1.7. General Health Testing
7.3.1.8. Others
7.3.2. Disease Risk Assessment Testing
7.3.2.1. Sexual Health Tests
7.3.2.1.1. HIV
7.3.2.1.2. Chlamydia
7.3.2.1.3. Others
7.3.2.2. Cancer Predisposition Tests
7.3.2.3. Others
7.3.3. CBC
7.3.4. Chronic Disease Testing
7.3.4.1. Diabetes Testing
7.3.4.2. Hypertension
7.3.4.3. Others
7.3.5. COVID-19 Testing
7.3.6. TSH Testing
7.3.7. Others
7.4. Market Attractiveness Analysis, by Test Type
8. Europe Direct-to-Consumer Laboratory Testing Market Analysis and Forecast, by Provider
8.1. Introduction & Definition
8.2. Key Findings / Developments
8.3. Market Value Forecast, by Provider, 2017–2031
8.3.1. Hospitals
8.3.2. Clinics
8.3.3. Speciality Labs
8.3.4. Diagnostic Centres
8.4. Market Attractiveness Analysis, by Provider
9. Germany Direct-to-Consumer Laboratory Testing Market Analysis and Forecast
9.1. Introduction
9.1.1. Key Findings
9.2. Market Value Forecast, by Sample Type, 2017–2031
9.2.1. Blood
9.2.2. Urine
9.2.3. Saliva
9.2.4. Others
9.3. Market Value Forecast, by Test Type, 2017–2031
9.3.1. Genetic Testing
9.3.1.1. Nutrigenetics Test
9.3.1.1.1. Weight Control
9.3.1.1.2. Lactose Intolerance
9.3.1.1.3. Others
9.3.1.2. Celiac Disease Test
9.3.1.3. Sports & Physical Activity Testing
9.3.1.4. Men's Health Tests
9.3.1.5. Women's Health Tests
9.3.1.6. Pregnancy & Prenatal Screening Test
9.3.1.7. General Health Testing
9.3.1.8. Others
9.3.2. Disease Risk Assessment Testing
9.3.2.1. Sexual Health Tests
9.3.2.1.1. HIV
9.3.2.1.2. Chlamydia
9.3.2.1.3. Others
9.3.2.2. Cancer Predisposition Tests
9.3.2.3. Others
9.3.3. CBC
9.3.4. Chronic Disease Testing
9.3.4.1. Diabetes Testing
9.3.4.2. Hypertension
9.3.4.3. Others
9.3.5. COVID-19 Testing
9.3.6. TSH Testing
9.3.7. Others
9.4. Market Value Forecast, by Provider, 2017–2031
9.4.1. Hospitals
9.4.2. Clinics
9.4.3. Speciality Labs
9.4.4. Diagnostic Centres
10. U.K. Direct-to-Consumer Laboratory Testing Market Analysis and Forecast
10.1. Introduction
10.1.1. Key Findings
10.2. Market Value Forecast, by Sample Type, 2017–2031
10.2.1. Blood
10.2.2. Urine
10.2.3. Saliva
10.2.4. Others
10.3. Market Value Forecast, by Test Type, 2017–2031
10.3.1. Genetic Testing
10.3.1.1. Nutrigenetics Test
10.3.1.1.1. Weight Control
10.3.1.1.2. Lactose Intolerance
10.3.1.1.3. Others
10.3.1.2. Celiac Disease Test
10.3.1.3. Sports & Physical Activity Testing
10.3.1.4. Men's Health Tests
10.3.1.5. Women's Health Tests
10.3.1.6. Pregnancy & Prenatal Screening Test
10.3.1.7. General Health Testing
10.3.1.8. Others
10.3.2. Disease Risk Assessment Testing
10.3.2.1. Sexual Health Tests
10.3.2.1.1. HIV
10.3.2.1.2. Chlamydia
10.3.2.1.3. Others
10.3.2.2. Cancer Predisposition Tests
10.3.2.3. Others
10.3.2.4. CBC
10.3.2.5. Chronic Disease Testing
10.3.2.5.1. Diabetes Testing
10.3.2.5.2. Hypertension
10.3.2.5.3. Others
10.3.2.6. COVID-110 Testing
10.3.2.7. TSH Testing
10.3.2.8. Others
10.4. Market Value Forecast, by Provider, 2017–2031
10.4.1. Hospitals
10.4.2. Clinics
10.4.3. Speciality Labs
10.4.4. Diagnostic Centres
11. France Direct-to-Consumer Laboratory Testing Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Market Value Forecast, by Sample Type, 2017–2031
11.2.1. Blood
11.2.2. Urine
11.2.3. Saliva
11.2.4. Others
11.3. Market Value Forecast, by Test Type, 2017–2031
11.3.1. Genetic Testing
11.3.1.1. Nutrigenetics Test
11.3.1.1.1. Weight Control
11.3.1.1.2. Lactose Intolerance
11.3.1.1.3. Others
11.3.1.2. Celiac Disease Test
11.3.1.3. Sports & Physical Activity Testing
11.3.1.4. Men's Health Tests
11.3.1.5. Women's Health Tests
11.3.1.6. Pregnancy & Prenatal Screening Test
11.3.1.7. General Health Testing
11.3.1.8. Others
11.3.2. Disease Risk Assessment Testing
11.3.2.1. Sexual Health Tests
11.3.2.1.1. HIV
11.3.2.1.2. Chlamydia
11.3.2.1.3. Others
11.3.2.2. Cancer Predisposition Tests
11.3.2.3. Others
11.3.3. CBC
11.3.4. Chronic Disease Testing
11.3.4.1. Diabetes Testing
11.3.4.2. Hypertension
11.3.4.3. Others
11.3.5. COVID-19 Testing
11.3.6. TSH Testing
11.3.7. Others
11.4. Market Value Forecast, by Provider, 2017–2031
11.4.1. Hospitals
11.4.2. Clinics
11.4.3. Speciality Labs
11.4.4. Diagnostic Centres
12. Italy Direct-to-Consumer Laboratory Testing Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast, by Sample Type, 2017–2031
12.2.1. Blood
12.2.2. Urine
12.2.3. Saliva
12.2.4. Others
12.3. Market Value Forecast, by Test Type, 2017–2031
12.3.1. Genetic Testing
12.3.1.1. Nutrigenetics Test
12.3.1.1.1. Weight Control
12.3.1.1.2. Lactose Intolerance
12.3.1.1.3. Others
12.3.1.2. Celiac Disease Test
12.3.1.3. Sports & Physical Activity Testing
12.3.1.4. Men's Health Tests
12.3.1.5. Women's Health Tests
12.3.1.6. Pregnancy & Prenatal Screening Test
12.3.1.7. General Health Testing
12.3.1.8. Others
12.3.2. Disease Risk Assessment Testing
12.3.2.1. Sexual Health Tests
12.3.2.1.1. HIV
12.3.2.1.2. Chlamydia
12.3.2.1.3. Others
12.3.2.2. Cancer Predisposition Tests
12.3.2.3. Others
12.3.3. CBC
12.3.4. Chronic Disease Testing
12.3.4.1. Diabetes Testing
12.3.4.2. Hypertension
12.3.4.3. Others
12.3.5. COVID-19 Testing
12.3.6. TSH Testing
12.3.7. Others
12.4. Market Value Forecast, by Provider, 2017–2031
12.4.1. Hospitals
12.4.2. Clinics
12.4.3. Speciality Labs
12.4.4. Diagnostic Centres
13. Spain Direct-to-Consumer Laboratory Testing Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast, by Sample Type, 2017–2031
13.2.1. Blood
13.2.2. Urine
13.2.3. Saliva
13.2.4. Others
13.3. Market Value Forecast, by Test Type, 2017–2031
13.3.1. Genetic Testing
13.3.1.1. Nutrigenetics Test
13.3.1.1.1. Weight Control
13.3.1.1.2. Lactose Intolerance
13.3.1.1.3. Others
13.3.1.2. Celiac Disease Test
13.3.1.3. Sports & Physical Activity Testing
13.3.1.4. Men's Health Tests
13.3.1.5. Women's Health Tests
13.3.1.6. Pregnancy & Prenatal Screening Test
13.3.1.7. General Health Testing
13.3.1.8. Others
13.3.2. Disease Risk Assessment Testing
13.3.2.1. Sexual Health Tests
13.3.2.1.1. HIV
13.3.2.1.2. Chlamydia
13.3.2.1.3. Others
13.3.2.2. Cancer Predisposition Tests
13.3.2.3. Others
13.3.3. CBC
13.3.4. Chronic Disease Testing
13.3.4.1. Diabetes Testing
13.3.4.2. Hypertension
13.3.4.3. Others
13.3.5. COVID-19 Testing
13.3.6. TSH Testing
13.3.7. Others
13.4. Market Value Forecast, by Provider, 2017–2031
13.4.1. Hospitals
13.4.2. Clinics
13.4.3. Speciality Labs
13.4.4. Diagnostic Centres
14. Rest of Europe Countries Direct-to-Consumer Laboratory Testing Market Analysis and Forecast
14.1. Introduction
14.1.1. Key Findings
14.2. Market Value Forecast, by Sample Type, 2017–2031
14.2.1. Blood
14.2.2. Urine
14.2.3. Saliva
14.2.4. Others
14.3. Market Value Forecast, by Test Type, 2017–2031
14.3.1. Genetic Testing
14.3.1.1. Nutrigenetics Test
14.3.1.1.1. Weight Control
14.3.1.1.2. Lactose Intolerance
14.3.1.1.3. Others
14.3.1.2. Celiac Disease Test
14.3.1.3. Sports & Physical Activity Testing
14.3.1.4. Men's Health Tests
14.3.1.5. Women's Health Tests
14.3.1.6. Pregnancy & Prenatal Screening Test
14.3.1.7. General Health Testing
14.3.1.8. Others
14.3.2. Disease Risk Assessment Testing
14.3.2.1. Sexual Health Tests
14.3.2.1.1. HIV
14.3.2.1.2. Chlamydia
14.3.2.1.3. Others
14.3.2.2. Cancer Predisposition Tests
14.3.2.3. Others
14.3.3. CBC
14.3.4. Chronic Disease Testing
14.3.4.1. Diabetes Testing
14.3.4.2. Hypertension
14.3.4.3. Others
14.3.5. COVID-19 Testing
14.3.6. TSH Testing
14.3.7. Others
14.4. Market Value Forecast, by Provider, 2017–2031
14.4.1. Hospitals
14.4.2. Clinics
14.4.3. Speciality Labs
14.4.4. Diagnostic Centres
15. Competition Landscape
15.1. Market Player - Competition Matrix (by tier and size of companies)
15.2. Company Profiles
15.2.1. 23andMe, Inc.
15.2.1.1. Company Description
15.2.1.2. Business Overview
15.2.1.3. Strategic Overview
15.2.1.4. SWOT Analysis
15.2.2. Ancestry
15.2.2.1. Company Description
15.2.2.2. Business Overview
15.2.2.3. SWOT Analysis
15.2.3. CircleDNA
15.2.3.1. Company Description
15.2.3.2. Business Overview
15.2.3.3. SWOT Analysis
15.2.4. Eurofins Scientific
15.2.4.1. Company Description
15.2.4.2. Business Overview
15.2.4.3. Financial Overview
15.2.4.4. SWOT Analysis
15.2.5. Family Tree DNA (Gene by Gene)
15.2.5.1. Company Description
15.2.5.2. Business Overview
15.2.5.3. SWOT Analysis
15.2.6. Laboratory Corporation of America Holdings
15.2.6.1. Company Description
15.2.6.2. Business Overview
15.2.6.3. Financial Overview
15.2.6.4. Strategic Overview
15.2.6.5. SWOT Analysis
15.2.7. Living DNA Ltd.
15.2.7.1. Company Description
15.2.7.2. Business Overview
15.2.7.3. SWOT Analysis
15.2.8. Medichecks.com Ltd.
15.2.8.1. Company Description
15.2.8.2. Business Overview
15.2.8.3. SWOT Analysis
15.2.9. MyHeritage Ltd.
15.2.9.1. Company Description
15.2.9.2. Business Overview
15.2.9.3. SWOT Analysis
15.2.10. MyMedLab, Inc.
15.2.10.1. Company Description
15.2.10.2. Business Overview
15.2.10.3. SWOT Analysis
15.2.11. Quest Diagnostics Incorporated
15.2.11.1. Company Description
15.2.11.2. Business Overview
15.2.11.3. Financial Overview
15.2.11.4. Strategic Overview
15.2.11.5. SWOT Analysis

 

ページTOPに戻る


 

Summary

Europe Direct-to-Consumer Laboratory Testing Market – Scope of Report

TMR’s report on the direct-to-consumer laboratory testing market in Europe studies the past as well as current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2021 to 2031. The report provides the revenue of the direct-to-consumer laboratory testing market in Europe for the period 2017–2031, considering 2020 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR) for the direct-to-consumer laboratory testing market in Europe for the forecast period.

The report has been prepared after an extensive research. Primary research involved bulk of research efforts, wherein analysts carried out interviews with industry leaders and opinion makers. Secondary research involved referring to key players’ product literature, annual reports, press releases, and relevant documents to understand the direct-to-consumer laboratory testing market in Europe.

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts have employed a combination of top-down and bottom-up approaches to study various phenomena in the direct-to-consumer laboratory testing market in Europe.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Furthermore, the report sheds light on the changing competitive dynamics in the direct-to-consumer laboratory testing market in Europe. These indices serve as valuable tools for existing market players as well as for entities interested in participating in the direct-to-consumer laboratory testing market in Europe. The next section of the direct-to-consumer laboratory testing market report highlights the USPs such as key industrial events (licensing partnership/merger & acquisition), disease epidemiology by region/country, COVID-19 pandemic impact on industry (value chain and short/mid/long-term impact), and key success factors of top players operating in the direct-to-consumer laboratory testing market in Europe.

The report also delves into the competition landscape of the direct-to-consumer laboratory testing market in Europe. Key players operating in the direct-to-consumer laboratory testing market in Europe have been identified, and each one of these has been profiled for distinguishing business attributes. Company overview, financial standings, recent developments, strategic overview, and SWOT are some of the attributes of players in the direct-to-consumer laboratory testing market in Europe profiled in this report.

Key Questions Answered in Europe Direct-to-Consumer Laboratory Testing Market Report

What are the major drivers, restraints, and opportunities in the market?
What are the revenue share projections of key segments of the direct-to-consumer laboratory testing market in Europe during the forecast period?
Which segment is likely to lead the direct-to-consumer laboratory testing market in Europe in terms of revenue by 2031?
How technological developments are widening the scope for the direct-to-consumer laboratory testing market in Europe?
What is the market position of different companies operating in the direct-to-consumer laboratory testing market in in Europe?
Europe Direct-to-Consumer Laboratory Testing Market – Research Objectives and Research Approach

The comprehensive report on the direct-to-consumer laboratory testing market in Europe begins with an overview of the market, followed by the scope and objectives of this study. Following this, the report provides detailed explanation of the objectives behind the study and healthcare compliances laid down by accredited agencies in the purview of research in the direct-to-consumer laboratory testing market in Europe. It is followed by market introduction, market dynamics, and an overview of the direct-to-consumer laboratory testing market in Europe, which includes TMR analysis of market drivers, restraints, and opportunities affecting the growth of the direct-to-consumer laboratory testing market in Europe. Furthermore, Y-o-Y analysis with elaborate insights has been provided to understand the Y-o-Y trends of the direct-to-consumer laboratory testing market in Europe.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The entire report comprises an exhaustive collection of graphs and tables that are appropriately interspersed in the entire compilation. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the direct-to-consumer laboratory testing market in in Europe in terms of test type, sample type, provider, and country. Key segments under each criteria have been studied at length, and the market share for each of these at the end of 2031 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investments in the direct-to-consumer laboratory testing market.



ページTOPに戻る


Table of Contents

1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Europe Direct-to-Consumer Laboratory Testing Market
4. Market Overview
4.1. Introduction
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Europe Direct-to-Consumer Laboratory Testing Market Analysis and Forecast, 2017–2031
4.4.1. Market Revenue Projections (US$ Mn)
5. Key Insights
5.1. Key Industrial Events (licensing partnerships/mergers & acquisitions)
5.2. Disease Prevalence & Incidence Rate
5.3. COVID-19 Pandemic Impact on Industry (value chain and short / mid / long term impact)
6. Europe Direct-to-Consumer Laboratory Testing Market Analysis and Forecast, by Sample Type
6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Market Value Forecast, by Sample Type, 2017–2031
6.3.1. Blood
6.3.2. Urine
6.3.3. Saliva
6.3.4. Others
6.4. Market Attractiveness Analysis, by Sample Type
7. Europe Direct-to-Consumer Laboratory Testing Market Analysis and Forecast, by Test Type
7.1. Introduction & Definition
7.2. Key Findings / Developments
7.3. Market Value Forecast, by Test Type, 2017–2031
7.3.1. Genetic Testing
7.3.1.1. Nutrigenetics Test
7.3.1.1.1. Weight Control
7.3.1.1.2. Lactose Intolerance
7.3.1.1.3. Others
7.3.1.2. Celiac Disease Test
7.3.1.3. Sports & Physical Activity Testing
7.3.1.4. Men's Health Tests
7.3.1.5. Women's Health Tests
7.3.1.6. Pregnancy & Prenatal Screening Test
7.3.1.7. General Health Testing
7.3.1.8. Others
7.3.2. Disease Risk Assessment Testing
7.3.2.1. Sexual Health Tests
7.3.2.1.1. HIV
7.3.2.1.2. Chlamydia
7.3.2.1.3. Others
7.3.2.2. Cancer Predisposition Tests
7.3.2.3. Others
7.3.3. CBC
7.3.4. Chronic Disease Testing
7.3.4.1. Diabetes Testing
7.3.4.2. Hypertension
7.3.4.3. Others
7.3.5. COVID-19 Testing
7.3.6. TSH Testing
7.3.7. Others
7.4. Market Attractiveness Analysis, by Test Type
8. Europe Direct-to-Consumer Laboratory Testing Market Analysis and Forecast, by Provider
8.1. Introduction & Definition
8.2. Key Findings / Developments
8.3. Market Value Forecast, by Provider, 2017–2031
8.3.1. Hospitals
8.3.2. Clinics
8.3.3. Speciality Labs
8.3.4. Diagnostic Centres
8.4. Market Attractiveness Analysis, by Provider
9. Germany Direct-to-Consumer Laboratory Testing Market Analysis and Forecast
9.1. Introduction
9.1.1. Key Findings
9.2. Market Value Forecast, by Sample Type, 2017–2031
9.2.1. Blood
9.2.2. Urine
9.2.3. Saliva
9.2.4. Others
9.3. Market Value Forecast, by Test Type, 2017–2031
9.3.1. Genetic Testing
9.3.1.1. Nutrigenetics Test
9.3.1.1.1. Weight Control
9.3.1.1.2. Lactose Intolerance
9.3.1.1.3. Others
9.3.1.2. Celiac Disease Test
9.3.1.3. Sports & Physical Activity Testing
9.3.1.4. Men's Health Tests
9.3.1.5. Women's Health Tests
9.3.1.6. Pregnancy & Prenatal Screening Test
9.3.1.7. General Health Testing
9.3.1.8. Others
9.3.2. Disease Risk Assessment Testing
9.3.2.1. Sexual Health Tests
9.3.2.1.1. HIV
9.3.2.1.2. Chlamydia
9.3.2.1.3. Others
9.3.2.2. Cancer Predisposition Tests
9.3.2.3. Others
9.3.3. CBC
9.3.4. Chronic Disease Testing
9.3.4.1. Diabetes Testing
9.3.4.2. Hypertension
9.3.4.3. Others
9.3.5. COVID-19 Testing
9.3.6. TSH Testing
9.3.7. Others
9.4. Market Value Forecast, by Provider, 2017–2031
9.4.1. Hospitals
9.4.2. Clinics
9.4.3. Speciality Labs
9.4.4. Diagnostic Centres
10. U.K. Direct-to-Consumer Laboratory Testing Market Analysis and Forecast
10.1. Introduction
10.1.1. Key Findings
10.2. Market Value Forecast, by Sample Type, 2017–2031
10.2.1. Blood
10.2.2. Urine
10.2.3. Saliva
10.2.4. Others
10.3. Market Value Forecast, by Test Type, 2017–2031
10.3.1. Genetic Testing
10.3.1.1. Nutrigenetics Test
10.3.1.1.1. Weight Control
10.3.1.1.2. Lactose Intolerance
10.3.1.1.3. Others
10.3.1.2. Celiac Disease Test
10.3.1.3. Sports & Physical Activity Testing
10.3.1.4. Men's Health Tests
10.3.1.5. Women's Health Tests
10.3.1.6. Pregnancy & Prenatal Screening Test
10.3.1.7. General Health Testing
10.3.1.8. Others
10.3.2. Disease Risk Assessment Testing
10.3.2.1. Sexual Health Tests
10.3.2.1.1. HIV
10.3.2.1.2. Chlamydia
10.3.2.1.3. Others
10.3.2.2. Cancer Predisposition Tests
10.3.2.3. Others
10.3.2.4. CBC
10.3.2.5. Chronic Disease Testing
10.3.2.5.1. Diabetes Testing
10.3.2.5.2. Hypertension
10.3.2.5.3. Others
10.3.2.6. COVID-110 Testing
10.3.2.7. TSH Testing
10.3.2.8. Others
10.4. Market Value Forecast, by Provider, 2017–2031
10.4.1. Hospitals
10.4.2. Clinics
10.4.3. Speciality Labs
10.4.4. Diagnostic Centres
11. France Direct-to-Consumer Laboratory Testing Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Market Value Forecast, by Sample Type, 2017–2031
11.2.1. Blood
11.2.2. Urine
11.2.3. Saliva
11.2.4. Others
11.3. Market Value Forecast, by Test Type, 2017–2031
11.3.1. Genetic Testing
11.3.1.1. Nutrigenetics Test
11.3.1.1.1. Weight Control
11.3.1.1.2. Lactose Intolerance
11.3.1.1.3. Others
11.3.1.2. Celiac Disease Test
11.3.1.3. Sports & Physical Activity Testing
11.3.1.4. Men's Health Tests
11.3.1.5. Women's Health Tests
11.3.1.6. Pregnancy & Prenatal Screening Test
11.3.1.7. General Health Testing
11.3.1.8. Others
11.3.2. Disease Risk Assessment Testing
11.3.2.1. Sexual Health Tests
11.3.2.1.1. HIV
11.3.2.1.2. Chlamydia
11.3.2.1.3. Others
11.3.2.2. Cancer Predisposition Tests
11.3.2.3. Others
11.3.3. CBC
11.3.4. Chronic Disease Testing
11.3.4.1. Diabetes Testing
11.3.4.2. Hypertension
11.3.4.3. Others
11.3.5. COVID-19 Testing
11.3.6. TSH Testing
11.3.7. Others
11.4. Market Value Forecast, by Provider, 2017–2031
11.4.1. Hospitals
11.4.2. Clinics
11.4.3. Speciality Labs
11.4.4. Diagnostic Centres
12. Italy Direct-to-Consumer Laboratory Testing Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast, by Sample Type, 2017–2031
12.2.1. Blood
12.2.2. Urine
12.2.3. Saliva
12.2.4. Others
12.3. Market Value Forecast, by Test Type, 2017–2031
12.3.1. Genetic Testing
12.3.1.1. Nutrigenetics Test
12.3.1.1.1. Weight Control
12.3.1.1.2. Lactose Intolerance
12.3.1.1.3. Others
12.3.1.2. Celiac Disease Test
12.3.1.3. Sports & Physical Activity Testing
12.3.1.4. Men's Health Tests
12.3.1.5. Women's Health Tests
12.3.1.6. Pregnancy & Prenatal Screening Test
12.3.1.7. General Health Testing
12.3.1.8. Others
12.3.2. Disease Risk Assessment Testing
12.3.2.1. Sexual Health Tests
12.3.2.1.1. HIV
12.3.2.1.2. Chlamydia
12.3.2.1.3. Others
12.3.2.2. Cancer Predisposition Tests
12.3.2.3. Others
12.3.3. CBC
12.3.4. Chronic Disease Testing
12.3.4.1. Diabetes Testing
12.3.4.2. Hypertension
12.3.4.3. Others
12.3.5. COVID-19 Testing
12.3.6. TSH Testing
12.3.7. Others
12.4. Market Value Forecast, by Provider, 2017–2031
12.4.1. Hospitals
12.4.2. Clinics
12.4.3. Speciality Labs
12.4.4. Diagnostic Centres
13. Spain Direct-to-Consumer Laboratory Testing Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast, by Sample Type, 2017–2031
13.2.1. Blood
13.2.2. Urine
13.2.3. Saliva
13.2.4. Others
13.3. Market Value Forecast, by Test Type, 2017–2031
13.3.1. Genetic Testing
13.3.1.1. Nutrigenetics Test
13.3.1.1.1. Weight Control
13.3.1.1.2. Lactose Intolerance
13.3.1.1.3. Others
13.3.1.2. Celiac Disease Test
13.3.1.3. Sports & Physical Activity Testing
13.3.1.4. Men's Health Tests
13.3.1.5. Women's Health Tests
13.3.1.6. Pregnancy & Prenatal Screening Test
13.3.1.7. General Health Testing
13.3.1.8. Others
13.3.2. Disease Risk Assessment Testing
13.3.2.1. Sexual Health Tests
13.3.2.1.1. HIV
13.3.2.1.2. Chlamydia
13.3.2.1.3. Others
13.3.2.2. Cancer Predisposition Tests
13.3.2.3. Others
13.3.3. CBC
13.3.4. Chronic Disease Testing
13.3.4.1. Diabetes Testing
13.3.4.2. Hypertension
13.3.4.3. Others
13.3.5. COVID-19 Testing
13.3.6. TSH Testing
13.3.7. Others
13.4. Market Value Forecast, by Provider, 2017–2031
13.4.1. Hospitals
13.4.2. Clinics
13.4.3. Speciality Labs
13.4.4. Diagnostic Centres
14. Rest of Europe Countries Direct-to-Consumer Laboratory Testing Market Analysis and Forecast
14.1. Introduction
14.1.1. Key Findings
14.2. Market Value Forecast, by Sample Type, 2017–2031
14.2.1. Blood
14.2.2. Urine
14.2.3. Saliva
14.2.4. Others
14.3. Market Value Forecast, by Test Type, 2017–2031
14.3.1. Genetic Testing
14.3.1.1. Nutrigenetics Test
14.3.1.1.1. Weight Control
14.3.1.1.2. Lactose Intolerance
14.3.1.1.3. Others
14.3.1.2. Celiac Disease Test
14.3.1.3. Sports & Physical Activity Testing
14.3.1.4. Men's Health Tests
14.3.1.5. Women's Health Tests
14.3.1.6. Pregnancy & Prenatal Screening Test
14.3.1.7. General Health Testing
14.3.1.8. Others
14.3.2. Disease Risk Assessment Testing
14.3.2.1. Sexual Health Tests
14.3.2.1.1. HIV
14.3.2.1.2. Chlamydia
14.3.2.1.3. Others
14.3.2.2. Cancer Predisposition Tests
14.3.2.3. Others
14.3.3. CBC
14.3.4. Chronic Disease Testing
14.3.4.1. Diabetes Testing
14.3.4.2. Hypertension
14.3.4.3. Others
14.3.5. COVID-19 Testing
14.3.6. TSH Testing
14.3.7. Others
14.4. Market Value Forecast, by Provider, 2017–2031
14.4.1. Hospitals
14.4.2. Clinics
14.4.3. Speciality Labs
14.4.4. Diagnostic Centres
15. Competition Landscape
15.1. Market Player - Competition Matrix (by tier and size of companies)
15.2. Company Profiles
15.2.1. 23andMe, Inc.
15.2.1.1. Company Description
15.2.1.2. Business Overview
15.2.1.3. Strategic Overview
15.2.1.4. SWOT Analysis
15.2.2. Ancestry
15.2.2.1. Company Description
15.2.2.2. Business Overview
15.2.2.3. SWOT Analysis
15.2.3. CircleDNA
15.2.3.1. Company Description
15.2.3.2. Business Overview
15.2.3.3. SWOT Analysis
15.2.4. Eurofins Scientific
15.2.4.1. Company Description
15.2.4.2. Business Overview
15.2.4.3. Financial Overview
15.2.4.4. SWOT Analysis
15.2.5. Family Tree DNA (Gene by Gene)
15.2.5.1. Company Description
15.2.5.2. Business Overview
15.2.5.3. SWOT Analysis
15.2.6. Laboratory Corporation of America Holdings
15.2.6.1. Company Description
15.2.6.2. Business Overview
15.2.6.3. Financial Overview
15.2.6.4. Strategic Overview
15.2.6.5. SWOT Analysis
15.2.7. Living DNA Ltd.
15.2.7.1. Company Description
15.2.7.2. Business Overview
15.2.7.3. SWOT Analysis
15.2.8. Medichecks.com Ltd.
15.2.8.1. Company Description
15.2.8.2. Business Overview
15.2.8.3. SWOT Analysis
15.2.9. MyHeritage Ltd.
15.2.9.1. Company Description
15.2.9.2. Business Overview
15.2.9.3. SWOT Analysis
15.2.10. MyMedLab, Inc.
15.2.10.1. Company Description
15.2.10.2. Business Overview
15.2.10.3. SWOT Analysis
15.2.11. Quest Diagnostics Incorporated
15.2.11.1. Company Description
15.2.11.2. Business Overview
15.2.11.3. Financial Overview
15.2.11.4. Strategic Overview
15.2.11.5. SWOT Analysis

 

ページTOPに戻る

ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

webからのご注文・お問合せはこちらのフォームから承ります

Transparency Market Research 社の最新刊レポート


よくあるご質問


Transparency Market Research社はどのような調査会社ですか?


トレンスペアレンシーマーケットリサーチ(Transparency Market Research /TMR)は市場参入やホワイトスペースの特定、新商品や新サービスの立ち上げ、戦略的M&Aなどの実現のた... もっと見る


調査レポートの納品までの日数はどの程度ですか?


在庫のあるものは速納となりますが、平均的には 3-4日と見て下さい。
但し、一部の調査レポートでは、発注を受けた段階で内容更新をして納品をする場合もあります。
発注をする前のお問合せをお願いします。


注文の手続きはどのようになっていますか?


1)お客様からの御問い合わせをいただきます。
2)見積書やサンプルの提示をいたします。
3)お客様指定、もしくは弊社の発注書をメール添付にて発送してください。
4)データリソース社からレポート発行元の調査会社へ納品手配します。
5) 調査会社からお客様へ納品されます。最近は、pdfにてのメール納品が大半です。


お支払方法の方法はどのようになっていますか?


納品と同時にデータリソース社よりお客様へ請求書(必要に応じて納品書も)を発送いたします。
お客様よりデータリソース社へ(通常は円払い)の御振り込みをお願いします。
請求書は、納品日の日付で発行しますので、翌月最終営業日までの当社指定口座への振込みをお願いします。振込み手数料は御社負担にてお願いします。
お客様の御支払い条件が60日以上の場合は御相談ください。
尚、初めてのお取引先や個人の場合、前払いをお願いすることもあります。ご了承のほど、お願いします。


データリソース社はどのような会社ですか?


当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
世界各国の「市場・技術・法規制などの」実情を調査・収集される時には、データリソース社にご相談ください。
お客様の御要望にあったデータや情報を抽出する為のレポート紹介や調査のアドバイスも致します。



詳細検索

このレポートへのお問合せ

03-3582-2531

電話お問合せもお気軽に

 

2024/09/19 10:28

144.64 円

160.77 円

193.27 円

ページTOPに戻る